|
03 Oct 2025 |
Zensar Technologies
|
Consensus Share Price Target
|
768.75 |
877.67 |
- |
14.17 |
buy
|
|
|
|
|
12 Jun 2019
|
Zensar Technologies
|
Motilal Oswal
|
768.75
|
300.00
|
257.00
(199.12%)
|
|
Buy
|
|
|
Hi-Tech remains the key vertical, which is expected to drive this digital growth. Customers from Independent Software Vendors (ISVs) and Internet/Social/Mobile (ISM) sub-segments are spending heavily on digital which needs to be tapped. Acquisition of Indigo Slate and Foolproof has helped add more clients in this segment.
|
|
07 May 2019
|
Zensar Technologies
|
Chola Wealth Direct
|
768.75
|
307.00
|
242.00
(217.67%)
|
|
Buy
|
|
|
Background Zensar Technologies is an RPG Group company, with end-to-end services from IT development to business process outsourcing. In 4QFY19: revenue share from services: Application Management Services (84.7%), Infrastructure Management Services (15.3%).The Company's business is primarily classified into Manufacturing (51.8%), Retail & Consumer services (21.6%), Financial Services (22.2%), and Emerging (4.4%). The company's business is spread across USA (76.2%), Europe (14.9%), Africa (8.0%) and RoW (0.9%). It receives 67.4% of revenues from onsite and 32.6% of revenues from offshore. Fixed price...
|
|
07 May 2019
|
Zensar Technologies
|
Karvy
|
768.75
|
270.00
|
237.65
(223.48%)
|
|
Hold
|
|
|
Strong set of numbers: At $150.1 Mn, Zensar (ZENT) reported a strong growth in revenue 4.5% QoQ and 18.5% YoY.
|
|
05 May 2019
|
Zensar Technologies
|
Prabhudas Lilladhar
|
768.75
|
260.00
|
245.95
(212.56%)
|
Target met |
Accumulate
|
|
|
Zensar's Q4FY19 was a beat on revenue at USD 150mn (Ple: USD 145mn) up Change in Estimates | Target | Reco 4.5% QoQ (4.1% cc terms). EBITDA margin improved by 134 bps QoQ to 12% (PLe: 11%) aided by operating leverage driven by stronger than expected...
|
|
02 May 2019
|
Zensar Technologies
|
HDFC Securities
|
768.75
|
305.00
|
246.50
(211.87%)
|
|
Buy
|
|
|
Zensar's organic growth has improved (+11.5% in FY19) led by robust deal wins. Total TCV for the quarter stood at USD 250mn (+25% QoQ) and USD 750mn in FY19 (vs USD 600mn in FY18). The deal pipe-line is healthy at USD 1bn, ~60% of the pipeline is large deals (TCV >USD 10mn). We believe growth will continue in FY20/21E led by Digital traction, ramp-up in deals won and healthy pipe-line. EBITDA margin will recover gradually to 12.7/13.5% in FY20/21E led by better mix. We maintain our positive view on Zensar based on (1) Focus on POC led Digital sales, (2) Robust deal wins and (3) Growth visibility in core business. We build 12/18/18% Revenue/EBITDA/PAT CAGR over FY19-21E. Zensar trades at ~10% discount to Tier-2 average P/E multiple with second highest FY19-21E EPS CAGR. Risks include delay in ramp-up of large deals, onsite wage inflation and deterioration in deal wins. We maintain BUY on Zensar post better than expected 4QFY19. Growth in TCV (+25% YoY) and robust deal pipeline of ~USD 1bn provides growth visibility. Our TP is Rs 305 implying 16x FY21E EPS. Zensar is one of our Top picks in Tier-2 IT.
|
|
02 May 2019
|
Zensar Technologies
|
Motilal Oswal
|
768.75
|
285.00
|
246.50
(211.87%)
|
|
Buy
|
|
|
17.6% YoY to USD567m, EBITDA increased 30% YoY to INR4,766m (margin of 12%) and PAT rose 31.8% YoY to INR 3,137m. Organic revenue growth was ~9% in USD terms and in double-digit on factoring in the RoW 2 May 2019 discontinuation and the impact from cross currencies. ZENT announced a total dividend of INR2.8/share for FY19, which implies a payout ratio of 20%. 4QFY19 revenue increased 19% YoY (above our estimate of +15% YoY) to USD150m, with 50% of incremental revenue coming from strong QoQ growth in the acquired entities. EBITDA margin expanded 160bp QoQ (our outperformance here was driven by higher operational income and other income (INR279m v/s our estimate of INR156m). While growth in FY19 (organically) was driven by Hi-tech and Insurance verticals, Manufacturing should add to it in FY20. Retail should take another couple of quarters before returning to sustained growth. ZENTs EBITDA margin in the core business is 14.1% (93.
|
|
24 Jan 2019
|
Zensar Technologies
|
Karvy
|
768.75
|
264.00
|
221.55
(246.99%)
|
|
Buy
|
|
|
In-line Revenues: Zensar Technologies (ZENT) posted revenues that were inline with our estimates. It posted a revenue growth of 4% in USD and in constant currency terms, revenue was up 4.5%. Of this growth, nearly half of this is contributed by integration of IndigoSlate numbers for the full quarter.
|
|
23 Jan 2019
|
Zensar Technologies
|
Chola Wealth Direct
|
768.75
|
307.00
|
224.50
(242.43%)
|
|
Buy
|
|
|
|
|
22 Jan 2019
|
Zensar Technologies
|
HDFC Securities
|
768.75
|
300.00
|
220.75
(248.24%)
|
|
Buy
|
|
|
Maintain BUY with a TP of Rs 300 based on 16x Dec-20 EPS. Zensar delivered robust revenue growth but margin performance was subdued. Revenue stood at USD 143.7mn (+4.0% QoQ, +4.5% CC) higher than our estimate of USD 141mn led by core business (+6.0% QoQ). Growth was led by sustained recovery in Cloud and Infrastructure Services (CIS) business (+16.9% QoQ, 17% of rev). EBITDA margin was below our estimate, contracted 204bps to 10.8% led by large deal transition impact, higher sub-con expenses and drop in utilisation.
|
|
22 Jan 2019
|
Zensar Technologies
|
Motilal Oswal
|
768.75
|
260.00
|
220.75
(248.24%)
|
Target met |
Buy
|
|
|
Revenue grew 17% YoY (our +30% YoY) to INR1,104m, while PAT declined 2% YoY to INR565m (1.5% miss). CC revenue growth of 4.5% QoQ (+17.6% YoY) was above our estimate 22 January 2019 of 3.2%. Excluding revenues from the full-quarter integration of IndigoSlate, revenue growth stood at 2.3%, implying that the beat to our estimate came from 59% QoQ growth in the acquired entity. For 9MFY19, USD revenue/EBITDA/PAT grew 17%/30%/39.5% YoY. 210bp QoQ to 10.6%, well below our estimate of 13.3%. Management attributed this to (i) transition costs in large deals (~120bp), (ii) furloughs (~50bp), (iii) margins contraction in non-core business (~40bp) and (iv) lower utilization (~50bp), partly offset by gain from INR depreciation. While management expects margins in the core business to revert to 15%, we are conservative in our estimates and expect overall EBITDA margin of 12.
|